Analysts Offer Predictions for UNCY Q4 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Free Report) – Equities researchers at Brookline Capital Markets issued their Q4 2026 earnings per share (EPS) estimates for Unicycive Therapeutics in a note issued to investors on Monday, November 16th. Brookline Capital Markets analyst K. Raja forecasts that the company will earn ($0.28) per share for the quarter. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($1.14) per share. Brookline Capital Markets also issued estimates for Unicycive Therapeutics’ FY2027 earnings at $3.93 EPS, FY2028 earnings at $3.46 EPS, FY2029 earnings at $4.35 EPS and FY2030 earnings at $3.33 EPS.

Several other equities analysts have also commented on the company. Benchmark reaffirmed a “speculative buy” rating and issued a $15.00 price target (up from $13.00) on shares of Unicycive Therapeutics in a research note on Thursday, August 20th. HC Wainwright cut their price objective on Unicycive Therapeutics from $15.00 to $13.00 and set a “buy” rating for the company in a research report on Tuesday, September 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Friday, September 4th. Guggenheim restated a “buy” rating and issued a $25.00 price objective (down from $37.00) on shares of Unicycive Therapeutics in a report on Thursday, August 13th. Finally, Zacks Research raised shares of Unicycive Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 19th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Unicycive Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.25.

Read Our Latest Stock Report on Unicycive Therapeutics

Unicycive Therapeutics Stock Down 3.5%

NASDAQ:UNCY opened at $3.57 on Thursday. Unicycive Therapeutics has a 52 week low of $3.33 and a 52 week high of $8.74. The company has a market capitalization of $104.19 million, a P/E ratio of -2.14 and a beta of 1.91. The stock’s fifty day moving average is $4.11 and its two-hundred day moving average is $5.89.

Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) last issued its quarterly earnings data on Monday, November 16th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.10.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. boosted its position in shares of Unicycive Therapeutics by 80.8% during the third quarter. Goldman Sachs Group Inc. now owns 262,767 shares of the company’s stock worth $1,234,000 after buying an additional 117,463 shares during the period. Dimensional Fund Advisors LP acquired a new stake in shares of Unicycive Therapeutics in the first quarter valued at $940,000. Seven Fleet Capital Management LP grew its stake in shares of Unicycive Therapeutics by 85.6% in the second quarter. Seven Fleet Capital Management LP now owns 103,400 shares of the company’s stock valued at $521,000 after buying an additional 47,700 shares in the last quarter. Virtu Financial LLC grew its stake in shares of Unicycive Therapeutics by 412.4% in the third quarter. Virtu Financial LLC now owns 59,484 shares of the company’s stock valued at $279,000 after buying an additional 47,874 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Unicycive Therapeutics in the 2nd quarter valued at $248,000. 40.42% of the stock is currently owned by institutional investors and hedge funds.

Recent Unicycive Therapeutics Headlines

Investors following UNCY have been watching these headlines:

  • Positive Sentiment: HC Wainwright raised its estimates for several periods, including FY2026 EPS to ($1.13) from ($1.38) and FY2027 to ($0.71) from ($0.86), while maintaining a Buy rating and $13 price target. The improved estimates could support sentiment. MarketBeat
  • Neutral Sentiment: Brookline Capital Markets issued markedly more optimistic long-range forecasts, projecting positive EPS from FY2027 onward. These are analyst projections and differ substantially from HC Wainwright’s outlook, so they add uncertainty rather than a clear consensus signal. MarketBeat
  • Negative Sentiment: Noble Financial lowered its FY2026 EPS estimate to ($0.80) from ($0.62), including a deeper projected Q4 loss. HC Wainwright also cut its FY2028–FY2030 EPS forecasts substantially, although it retained its Buy rating and $13 target; these longer-term reductions may weigh on investor expectations. MarketBeat

Unicycive Therapeutics Company Profile

(Get Free Report)

Unicycive Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Its lead program, oxylanthanum carbonate (OLC), is an oral phosphate binder being developed to help manage hyperphosphatemia, or elevated blood phosphate levels, in people with chronic kidney disease, including patients receiving dialysis. The company is also developing UNI-494, an investigational small-molecule therapy for acute kidney injury. These programs reflect Unicycive’s focus on conditions for which treatment options may be limited.

Featured Articles

Earnings History and Estimates for Unicycive Therapeutics (NASDAQ:UNCY)

Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.